<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03866499</url>
  </required_header>
  <id_info>
    <org_study_id>BPI-7711301</org_study_id>
    <nct_id>NCT03866499</nct_id>
  </id_info>
  <brief_title>A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients</brief_title>
  <official_title>A Randomized, Double-blind, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of BPI-7711 Capsule in Locally Advanced or Recurrent/Metastatic Treatment-naïve Non-small Cell Lung Cancer Patients With EGFR Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beta Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beta Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, positive controlled phase III study to evaluate the efficacy and
      safety of BPI-7711 capsule in locally advanced or recurrent/metastatic treatment-naïve
      non-small cell lung cancer patients with EGFR mutation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase III clinical study, which aims to compare the efficacy and safety of BPI-7711
      capsule and gefitinib tablet in the treatment of initially-treated patients with locally
      advanced or recurrent metastatic with EGFR mutation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>up to approximately 16 months</time_frame>
    <description>Progression-free survival evaluated by Blinded Independent Center Review</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>up to approximately 16 months</time_frame>
    <description>Progression-free survival evaluated by investigators</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>up to approximately 16 months</time_frame>
    <description>Objective response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best objective response</measure>
    <time_frame>up to approximately 16 months</time_frame>
    <description>Best objective response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>up to approximately 16 months</time_frame>
    <description>Disease control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>up to approximately 16 months</time_frame>
    <description>Duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to approximately 30 months</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">294</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>BPI-7711</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>180 mg BPI-7711 capsule + 250mg gefitinib placebo tablet, QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gefitinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>180 mg BPI-7711 placebo capsule + 250mg gefitinib tablet, QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BPI-7711</intervention_name>
    <description>180 mg, oral, QD</description>
    <arm_group_label>BPI-7711</arm_group_label>
    <other_name>BPI-7711 capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
    <description>250 mg, oral, QD</description>
    <arm_group_label>Gefitinib</arm_group_label>
    <other_name>Iressa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Tablet</intervention_name>
    <description>250 mg gefitinib placebo tablet, QD</description>
    <arm_group_label>BPI-7711</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsule</intervention_name>
    <description>180 mg BPI-7711 placebo capsule, QD</description>
    <arm_group_label>Gefitinib</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed non-small cell lung cancer.

          -  The ECOG score of performance status is 0-1.

          -  Locally advanced or recurrent metastatic NSCLC that has never received systemic
             treatment.

          -  According to RECIST1.1 criteria, there is at least 1 measurable lesion that has not
             been previously irradiated.

          -  Prior to enrollment, a central laboratory testing report has confirmed that the tumor
             has one of two common EGFR mutations positive that are sensitive to EGFR-TKI therapy,
             accompanied with or not accompanied with other EGFR mutation, with the exception of
             exon 20 insertion.

        Exclusion Criteria:

          -  Previously received systemic treatment for locally advanced or recurrent metastatic
             cancer.

          -  Primary T790M mutation-positive patient.

          -  Previous interstitial lung disease, drug-induced interstitial lung disease, radiation
             pneumonia requiring hormonal therapy, or any clinically proven active interstitial
             lung disease.

          -  Known active infections such as hepatitis B, hepatitis C, and human immunodeficiency
             virus.

          -  Local radiation therapy is carried out within 1 week; more than 30% bone marrow
             radiation therapy or extensive radiation therapy is performed within 4 weeks.

          -  ≤ 4 weeks from major surgery or ≤ 2 weeks from minor surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuankai Shi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenxiang Lu</last_name>
    <phone>+86 021-62165501</phone>
    <email>wenxiang.lu@betapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuankai Shi, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Puyuan Xing, PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Yuankai Shi, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingya Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linyi Cancer Hospital</name>
      <address>
        <city>Linyi</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianhua Shi</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 5, 2019</study_first_submitted>
  <study_first_submitted_qc>March 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EGFR</keyword>
  <keyword>T790M</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

